Sputnik V received an emergency nod from the Subject Expert Committee of the Central Drugs Standard Control Organization (CDSCO) and will become India's third vaccine after Covishield and Covaxin.
The Russians were the first to come up with a Covid vaccine in August last year. The name of the vaccine invoked the space race of the 1950s. Sputnik V met with controversy early on as it was rolled out even before conducting a phase 3 trial in Russia.
The vaccine has been funded by the Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund.
Interim phase 3 data, the results of which came out in February, showed that the vaccine had an efficacy of almost 92% making it one of the most effective Covid shots in the world.
Sputnik V uses a cold-type virus to deliver a small part of the coronavirus spike protein to the body and help develop an immune response to it. It works in the same way as the Oxford/Astrazeneca vaccine.
The only difference is that Sputnik uses two different vectors in two doses which are 21 days apart unlike other vaccines. This makes the immune response stronger to confront the coronavirus.
Moreover, the vaccine can be stored at 2-8 degree celsius which makes it convenient to use in Indian weather.
The Sputnik V vaccine will boost India's capability to take its vaccination drive forward.
India is currently in the grip of a second wave of Covid-19 with Maharashtra particularly bearing the brunt of the second surge.
India has two approved vaccines, Covishield and Covaxin. The DCGI will give the final go ahead to Sputnik V. That will be a shot in the arm for India's vaccination drive.
Russia's RDIF partnered with Dr Reddy's to conduct clinical trials of Sputnik V and for its distribution rights in India.
The Russians were the first to come up with a Covid vaccine in August last year. The name of the vaccine invoked the space race of the 1950s. Sputnik V met with controversy early on as it was rolled out even before conducting a phase 3 trial in Russia.
The vaccine has been funded by the Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund.
Interim phase 3 data, the results of which came out in February, showed that the vaccine had an efficacy of almost 92% making it one of the most effective Covid shots in the world.
Sputnik V uses a cold-type virus to deliver a small part of the coronavirus spike protein to the body and help develop an immune response to it. It works in the same way as the Oxford/Astrazeneca vaccine.
The only difference is that Sputnik uses two different vectors in two doses which are 21 days apart unlike other vaccines. This makes the immune response stronger to confront the coronavirus.
Moreover, the vaccine can be stored at 2-8 degree celsius which makes it convenient to use in Indian weather.
The Sputnik V vaccine will boost India's capability to take its vaccination drive forward.
India is currently in the grip of a second wave of Covid-19 with Maharashtra particularly bearing the brunt of the second surge.
India has two approved vaccines, Covishield and Covaxin. The DCGI will give the final go ahead to Sputnik V. That will be a shot in the arm for India's vaccination drive.
Russia's RDIF partnered with Dr Reddy's to conduct clinical trials of Sputnik V and for its distribution rights in India.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
7 Comments on this Story
 | saurabh parmar36 minutes ago modi ji will import from Russia and will export to other countries in the name of goodwill and will leave Indians with limited supplies of covishield and covaxin. |
 | Ghanshyam Gupta37 minutes ago Is there any evidence of clotting adverse effect with Sputnik as seen with Covishield vaccine? |
| Ashish Ramchandran45 minutes ago Hope the public gets to choose the vaccine unlike now where only Covishield is available for the masses whereas Covaxin for VVIP's |